Evidence Explorer · MS-N239 · Exercise and rehabilitation · progression-free survival and wellbeing · Appraised November 5, 2026
A large randomized trial reported that a telephone-supported exercise program during first-line chemotherapy did not improve progression-free survival or physical wellbeing. The result is important precisely because it is negative: exercise can still support general health, but this trial does not justify presenting it as a way to delay ovarian-cancer progression.
Evidence at a glance
- Benefit signal: No demonstrated improvement in progression-free survival, physical wellbeing or the reported secondary outcomes.
- Certainty: Moderate for the reported null result, but the efficacy results are currently available as a conference abstract rather than a peer-reviewed full primary report.
- Risk context: No grade 3 or higher exercise-related adverse events were reported; lower-grade events and detailed adherence harms need the full report.
- Cancer-control relevance: Directly studied progression-free survival and found no benefit; it does not show worse overall survival, and it does not negate supportive benefits outside the trial’s tested outcomes.
What was studied
The phase III ECHO trial randomized 489 eligible participants receiving first-line chemotherapy for ovarian cancer: 243 to exercise and 246 to usual care. Seventy-four percent had stage III or IV disease and the mean age was 61 years.
The intervention used individualized, telephone-supported mixed-mode exercise with a target of 150 minutes per week during chemotherapy. The reported median was 135 minutes per week. Median follow-up was 4.5 years.
What the study found
Progression-free-survival events occurred in 159 exercise-group participants and 148 controls. Median progression-free survival was 24 versus 23 months; hazard ratio 1.09 (95% CI 0.87 to 1.36; p=0.45).
The between-group difference in physical wellbeing was 0.11 points (95% CI −0.66 to 0.87; p=0.78). The conference report stated that secondary outcomes also did not differ.
What this does not establish
The public efficacy report is a conference abstract, so complete methods, missing-data handling, all adverse events, prespecified subgroup analyses, funding and conflicts have not yet been fully appraised. Registration and a published protocol establish the intended design, but registration alone is not proof of efficacy.
Safety and practical context
Exercise during chemotherapy may need to pause or change for fever, severe anemia, uncontrolled symptoms, thrombosis, cardiopulmonary instability or infection risk. A cancer-exercise professional can adjust intensity and mode.
No grade 3 or higher exercise-related adverse events were reported in the conference abstract; absence of reported severe events is not the same as proof of safety for every patient.
Questions for the care team
- What symptoms, blood-count thresholds or treatment complications should change the exercise plan?
- Is referral to cancer rehabilitation or an exercise physiologist available?
- Which supportive goals—function, fatigue, sleep or mood—matter most even though tumor control was not improved?
Sources and identifiers
- ECHO phase III results (conference abstract) — conference report; checked November 5, 2026
- ECHO trial protocol — PMID 37055210 — protocol, not an efficacy result
Funding and conflicts: Not verified from the conference abstract available for this appraisal; the full primary report is awaited.
Source access and dates: Conference abstract and protocol were accessible; full peer-reviewed primary results were not verified. Sources checked November 5, 2026. Last literature search November 5, 2026.
Educational evidence summary, not individualized medical advice. Exercise around cancer treatment should be adapted to symptoms, blood counts, bone health, cardiopulmonary status, surgical restrictions and the treating team’s guidance.
